168 related articles for article (PubMed ID: 33741225)
1. Late onset Pompe Disease in India - Beyond the Caucasian phenotype.
Puri RD; Setia N; N V; Jagadeesh S; Nampoothiri S; Gupta N; Muranjan M; Bhat M; Girisha KM; Kabra M; Verma J; Thomas DC; Biji I; Raja J; Makkar R; Verma IC; Kishnani PS
Neuromuscul Disord; 2021 May; 31(5):431-441. PubMed ID: 33741225
[TBL] [Abstract][Full Text] [Related]
2. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.
Rairikar MV; Case LE; Bailey LA; Kazi ZB; Desai AK; Berrier KL; Coats J; Gandy R; Quinones R; Kishnani PS
Mol Genet Metab; 2017 Nov; 122(3):99-107. PubMed ID: 28951071
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease.
Kishnani PS; Gibson JB; Gambello MJ; Hillman R; Stockton DW; Kronn D; Leslie ND; Pena LDM; Tanpaiboon P; Day JW; Wang RY; Goldstein JL; An Haack K; Sparks SE; Zhao Y; Hahn SH;
Genet Med; 2019 Nov; 21(11):2543-2551. PubMed ID: 31086307
[TBL] [Abstract][Full Text] [Related]
4. Homozygosity for the common GAA gene splice site mutation c.-32-13T>G in Pompe disease is associated with the classical adult phenotypical spectrum.
Musumeci O; Thieme A; Claeys KG; Wenninger S; Kley RA; Kuhn M; Lukacs Z; Deschauer M; Gaeta M; Toscano A; Gläser D; Schoser B
Neuromuscul Disord; 2015 Sep; 25(9):719-24. PubMed ID: 26231297
[TBL] [Abstract][Full Text] [Related]
5. Late Onset Pompe Disease with Novel Mutations and Atypical Phenotypes.
Chawla T; Preethish-Kumar V; Polavarapu K; Vengalil S; Bardhan M; Puri R; Verma J; Christopher R; Supriya M; Nashi S; Prasad C; Nadeesh B; Nalini A
J Neuromuscul Dis; 2022; 9(2):261-273. PubMed ID: 34864681
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic implications of pathogenic variant types in Pompe disease.
Viamonte MA; Filipp SL; Zaidi Z; Gurka MJ; Byrne BJ; Kang PB
J Hum Genet; 2021 Nov; 66(11):1089-1099. PubMed ID: 33972680
[TBL] [Abstract][Full Text] [Related]
7. Early-onset of symptoms and clinical course of Pompe disease associated with the c.-32-13 T > G variant.
Herbert M; Case LE; Rairikar M; Cope H; Bailey L; Austin SL; Kishnani PS
Mol Genet Metab; 2019 Feb; 126(2):106-116. PubMed ID: 30655185
[TBL] [Abstract][Full Text] [Related]
8. [GAA gene variants and genotype-phenotype correlations in patients with glycogen storage disease type Ⅱ].
Huang YL; Sheng HY; Jia XF; Su XY; Zhao XY; Xie T; Tang CF; Liu SC; Li XZ; Zhang W; Mei HF; Zeng CH; Liu L
Zhonghua Er Ke Za Zhi; 2021 Mar; 59(3):189-194. PubMed ID: 33657692
[No Abstract] [Full Text] [Related]
9. A genetic modifier of symptom onset in Pompe disease.
Bergsma AJ; In 't Groen SLM; van den Dorpel JJA; van den Hout HJMP; van der Beek NAME; Schoser B; Toscano A; Musumeci O; Bembi B; Dardis A; Morrone A; Tummolo A; Pasquini E; van der Ploeg AT; Pijnappel WWMP
EBioMedicine; 2019 May; 43():553-561. PubMed ID: 30922962
[TBL] [Abstract][Full Text] [Related]
10. Pompe disease in a Brazilian series: clinical and molecular analyses with identification of nine new mutations.
Oba-Shinjo SM; da Silva R; Andrade FG; Palmer RE; Pomponio RJ; Ciociola KM; S Carvalho M; Gutierrez PS; Porta G; Marrone CD; Munoz V; Grzesiuk AK; Llerena JC; Berditchevsky CR; Sobreira C; Horovitz D; Hatem TP; Frota ER; Pecchini R; Kouyoumdjian JA; Werneck L; Amado VM; Camelo JS; Mattaliano RJ; Marie SK
J Neurol; 2009 Nov; 256(11):1881-90. PubMed ID: 19588081
[TBL] [Abstract][Full Text] [Related]
11. An integrative correlation of myopathology, phenotype and genotype in late onset Pompe disease.
Kulessa M; Weyer-Menkhoff I; Viergutz L; Kornblum C; Claeys KG; Schneider I; Plöckinger U; Young P; Boentert M; Vielhaber S; Mawrin C; Bergmann M; Weis J; Ziagaki A; Stenzel W; Deschauer M; Nolte D; Hahn A; Schoser B; Schänzer A
Neuropathol Appl Neurobiol; 2020 Jun; 46(4):359-374. PubMed ID: 31545528
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing.
Lévesque S; Auray-Blais C; Gravel E; Boutin M; Dempsey-Nunez L; Jacques PE; Chenier S; Larue S; Rioux MF; Al-Hertani W; Nadeau A; Mathieu J; Maranda B; Désilets V; Waters PJ; Keutzer J; Austin S; Kishnani P
Orphanet J Rare Dis; 2016 Jan; 11():8. PubMed ID: 26809617
[TBL] [Abstract][Full Text] [Related]
13. Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease.
Savarese M; Torella A; Musumeci O; Angelini C; Astrea G; Bello L; Bruno C; Comi GP; Di Fruscio G; Piluso G; Di Iorio G; Ergoli M; Esposito G; Fanin M; Farina O; Fiorillo C; Garofalo A; Giugliano T; Magri F; Minetti C; Moggio M; Passamano L; Pegoraro E; Picillo E; Sampaolo S; Santorelli FM; Semplicini C; Udd B; Toscano A; Politano L; Nigro V
Neuromuscul Disord; 2018 Jul; 28(7):586-591. PubMed ID: 29880332
[TBL] [Abstract][Full Text] [Related]
14. Mutational spectrum and genotype-phenotype correlation in Mexican patients with infantile-onset and late-onset Pompe disease.
Martinez-Montoya V; Sánchez-Sánchez LM; Sandoval-Pacheco R; Castro DMA; Arellano-Valdez CA; Ávila-Rejón CA; Aguilar-Juárez PA; Espino-Pluma M; González-Santillanes CA; Martínez-Segovia RI; Olmos-Morfin D; la Torre OP; Solís-Sánchez I; Espinosa MVM; Villarroel-Cortés CE; Velarde-Félix JS; López-Valdez J; Olaiz-Urbina J; Ricárdez-Marcial E; Vergara-Sánchez I; Radillo-Díaz P; Kazakova E; De la Fuente-Cortez B; Del Carmen Marquez-Quiróz L; Torres-Octavo B; Diaz-Martinez R
Mol Genet Genomic Med; 2024 Jul; 12(7):e2480. PubMed ID: 38958145
[TBL] [Abstract][Full Text] [Related]
15. Screening for late-onset Pompe disease in Poland.
Jastrzębska A; Potulska-Chromik A; Łusakowska A; Jastrzębski M; Lipowska M; Kierdaszuk B; Kamińska A; Kostera-Pruszczyk A
Acta Neurol Scand; 2019 Oct; 140(4):239-243. PubMed ID: 31125121
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of lysosomal enzyme activity and genetic variants in a child with late-onset Pompe disease].
He T; Jiang J; Xiong Y; Yu D; Zhang X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Jun; 40(6):711-717. PubMed ID: 37212008
[TBL] [Abstract][Full Text] [Related]
17. Clinical manifestations and acid alpha-glucosidase mutation characterisation of a cohort of patients with late-onset Pompe disease in eastern China.
Zhao HH; Ma Z; Ying ZX; Niu FN; Luo MT; Wang Z; Cheng X; Zhang QQ; Niu Q
Ann Transl Med; 2021 Dec; 9(24):1803. PubMed ID: 35071497
[TBL] [Abstract][Full Text] [Related]
18. Novel GAA sequence variant c.1211 A>G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease.
Nilsson MI; Kroos MA; Reuser AJ; Hatcher E; Akhtar M; McCready ME; Tarnopolsky MA
Gene; 2014 Mar; 537(1):41-5. PubMed ID: 24384324
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
[TBL] [Abstract][Full Text] [Related]
20. Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study.
Semplicini C; Letard P; De Antonio M; Taouagh N; Perniconi B; Bouhour F; Echaniz-Laguna A; Orlikowski D; Sacconi S; Salort-Campana E; Solé G; Zagnoli F; Hamroun D; Froissart R; Caillaud C; Laforêt P;
J Inherit Metab Dis; 2018 Nov; 41(6):937-946. PubMed ID: 30155607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
